Enadenotucirev-expressing FAP/CD3 bispecific FAP-TAc NG-641

{
  "id": "MLC-T-ONC-013332",
  "term": "Enadenotucirev-expressing FAP/CD3 bispecific FAP-TAc NG-641",
  "field": "Oncology and biomedicine",
  "definition": "An oncolytic adenoviral vector, a transgene-modified variant of enadenotucirev (EnAd), that expresses a bi-specific T-cell activator molecule FAP-TAc together with immune enhancer molecules C-X-C motif chemokine 9 (CXCL9), C-X-C motif chemokine 10 (CXCL10) and interferon alpha (IFNalpha), with potential immunomodulating and antineoplastic activities. Upon administration of NG-641, EnAd specifically infects and replicates in tumor cells and not in normal, noncancerous tissue, and selectively expresses FAP-TAc. The locally expressed FAP-TAc targets and binds to both fibroblast activating protein (FAP) on cancer associated fibroblasts (CAFs) and CD3 on T cells. This leads to T-cell activation and T-cell mediated killing of CAFs in tumor stroma. NG-641 also encodes the transgenes CXCL9, CXCL10 and IFNalpha. The production of CXCL9, CXCL10 and IFNalpha leads to the recruitment and further activation of T cells, enhancing the overall immune response and cancer cell killing. FAP, a cell surface glycoprotein, is overexpressed on tumor-associated fibroblasts but minimally expressed on normal, healthy cells.",
  "synonyms": [
    "oncolytic adenoviral vector-expressing FAP/CD3 bispecific FAP-TAc NG-641",
    "oncolytic adenoviral vector expressing FAP/CD3 bispecific molecule NG-641"
  ],
  "references": [
    "National Cancer Institute Thesaurus"
  ],
  "url": "https://mlchart.com/terminology/oncology/enadenotucirev-expressing-fap-cd3-bispecific-fap-tac-ng-641/"
}